Electromed (ELMD) Stock Price, News & Analysis

Company Overview

Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. The company offers its products to hospitals, home health care centers, pulmonary rehabilitation centers, cystic fibrosis centers, neuromuscular clinics, and other clinics through distributors. It markets its products to physicians, health care providers, and directly to patients. Electromed, Inc. was incorporated in 1992 and is headquartered in New Prague, Minnesota.

Key Stats

• Today's Range: $24.17 to $24.80
• 50-Day Range: $18.13 to $24.77
• 52-Week Range: $15.06 to $35.56
• Volume: 58,147 shs
• Average Volume: 83,840 shs
• Market Capitalization: $206.79 million
• P/E Ratio: 32.89
• Dividend Yield: N/A
• Price Target: $36.25
• Consensus Rating: Buy

Electromed Stock Analysis - MarketRank™

Electromed scored higher than 50% of companies evaluated by MarketBeat, and ranked 561st out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Buy

Consensus Rating

Electromed has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Electromed has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Electromed is 32.89, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 28.62.

Price to Earnings Ratio vs. Sector

The P/E ratio of Electromed is 32.89, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 31.45.

Price to Book Value per Share Ratio

Electromed has a P/B Ratio of 4.84. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.32% of the float of Electromed has been sold short.

Short Interest Ratio / Days to Cover

Electromed has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Electromed has recently increased by 5.34%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Electromed does not currently pay a dividend.

Dividend Growth

Electromed does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

4.32% of the float of Electromed has been sold short.

Short Interest Ratio / Days to Cover

Electromed has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Electromed has recently increased by 5.34%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.67

News Sentiment

Electromed has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.03 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 30 news articles for Electromed this week, compared to 2 articles on an average week.

Search Interest

3 people have searched for ELMD on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Electromed to their MarketBeat watchlist in the last 30 days. This is a decrease of -88% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Electromed insiders have not sold or bought any company stock.

Percentage Held by Insiders

14.00% of the stock of Electromed is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

40.82% of the stock of Electromed is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ELMD Stock Analysis - Frequently Asked Questions

How have ELMD shares performed this year?

Electromed's stock was trading at $29.55 at the start of the year. Since then, ELMD shares have decreased by 16.6% and is now trading at $24.6590.

How were Electromed's earnings last quarter?

Electromed, Inc. (NYSE:ELMD) issued its quarterly earnings data on Tuesday, November, 12th. The company reported $0.16 earnings per share for the quarter, beating the consensus estimate of $0.03 by $0.13. The company had revenue of $14.67 million for the quarter. Electromed had a net margin of 11.34% and a trailing twelve-month return on equity of 15.71%.

How will Electromed's stock buyback program work?

Electromed's Board of Directors approved a share repurchase program on Monday, March 10th 2025, which authorizes the company to repurchase $5,000,000 in outstanding shares, according to EventVestor. This means that the company could buy up to 2.4% of its shares through open market purchases. Shares buyback programs are often a sign that the company's board of directors believes its shares are undervalued.

Who are Electromed's major shareholders?

Top institutional shareholders of Electromed include Acadian Asset Management LLC (2.84%), Geode Capital Management LLC (1.85%), Gamco Investors INC. ET AL (1.69%) and Hunter Associates Investment Management LLC (1.28%). Insiders that own company stock include Andrew Summers and Kathleen Skarvan.
View institutional ownership trends.

How do I buy shares of Electromed?

Shares of ELMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Electromed own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Electromed investors own include NVIDIA (NVDA), Enterprise Products Partners (EPD), Energy Transfer (ET), Meta Platforms (META), Pfizer (PFE), TransEnterix (TRXDW) and Avino Silver & Gold Mines (ASM).

Company Calendar

• Last Earnings: 11/12/2024
• Today: 8/29/2025
• Fiscal Year End: 6/30/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Electromedical equipment
• Sub-Industry: Medical Equipment
• Current Symbol: NYSE:ELMD
• CIK: 1488917
• Web: smartvest.com
• Phone: (952) 758-9299
• Fax: 866-758-5077
• Employees: 160
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Electromed: $36.25
• High Price Target: $38.00
• Low Price Target: $35.00
• Potential Upside/Downside: +47.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.79
• Trailing P/E Ratio: 32.89
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $5.15 million
• Net Margins: 11.34%
• Pretax Margin: 15.57%
• Return on Equity: 15.71%
• Return on Assets: 13.37%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.10
• Quick Ratio: 4.74

Sales & Book Value

• Annual Sales: $61.44 million
• Price / Sales: 3.37
• Cash Flow: $0.60 per share
• Price / Cash Flow: 41.36
• Book Value: $5.10 per share
• Price / Book: 4.84

Miscellaneous

• Outstanding Shares: 8,386,000
• Free Float: 7,359,000
• Market Cap: $206.79 million
• Optionable: Optionable
• Beta: 0.38